High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis

Denosumab is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL) that is used for the treatment of osteoporosis. Denosumab-induced hypocalcemia is a rare but important adverse event, which is usually asymptomatic in patients with osteoporosis. It is a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Interv Aging
Autors principals: Ishikawa, Koji, Nagai, Takashi, Tsuchiya, Koki, Oshita, Yusuke, Kuroda, Takuma, Ito, Hiroshi, Tani, Soji, Dodo, Yusuke, Toyone, Tomoaki, Inagaki, Katsunori
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6183698/
https://ncbi.nlm.nih.gov/pubmed/30349211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CIA.S180614
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars